Rib-X Pharmaceuticals, Inc., a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the issuance of a key antibiotic patent in China. The State Intellectual Property Office of the People's Republic of China has issued Chinese Patent Number ZL 2004 8 0021883.9 to Rib-X. This patent provides composition of matter protection for Rib-X's novel oxazolidinone antibiotic, radezolid. Rib-X has established a broad patent portfolio related to radezolid, including the issuance of composition of matter for radezolid in the US. The Company anticipates issuance of additional patents in all major and emerging markets.
The details can be read here.
No comments:
Post a Comment